van Reekum R, Simard M, Cohen T
Department of Psychiatry and Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, University of Toronto, Ont.
J Psychiatry Neurosci. 1999 Nov;24(5):413-30.
This paper sets a research agenda for the prediction and prevention of future onset of Alzheimer's disease (AD). From a MEDLINE review of the literature, the authors found age to be a predictor of AD. The literature also indicates that memory and attentional impairments predict AD, although the relative risk is relatively low. Late-onset depression may also predict AD, but these data are limited by a lack of cohort studies. Studying cognitively impaired subjects with late-onset depression may identify a high-risk group, facilitating prevention trials. Characteristics of an "ideal" preventive agent are suggested. There is a biologic rationale, and preliminary evidence, that non-steroidal anti-inflammatory drugs (including ASA), estrogen and vitamin E may play a preventive role in AD. Other compounds (such as acetylcholinesterase inhibitors) are also promising, but costs, side effects, and lack of other health benefits may preclude their use in all but very high-risk groups.
本文为阿尔茨海默病(AD)未来发病的预测和预防设定了一个研究议程。通过对MEDLINE文献的回顾,作者发现年龄是AD的一个预测因素。文献还表明,记忆和注意力障碍可预测AD,尽管相对风险较低。晚发性抑郁症也可能预测AD,但这些数据因缺乏队列研究而受到限制。研究患有晚发性抑郁症的认知受损受试者可能会识别出一个高危群体,从而促进预防试验。文中提出了“理想”预防药物的特征。有生物学依据和初步证据表明,非甾体抗炎药(包括阿司匹林)、雌激素和维生素E可能在AD中发挥预防作用。其他化合物(如乙酰胆碱酯酶抑制剂)也很有前景,但成本、副作用以及缺乏其他健康益处可能会限制其仅用于极高危群体。